Expertise in
4
conditions

Matteo D. Porta

Milan, IT 
Expertise in
4
conditions
Milan, IT 

Overview

Matteo Porta practices practicing medicine in Milan, Italy.

Porta is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Myelodysplastic Syndrome (MDS), Leukemia, Anemia, Bone Marrow Transplant, and Endoscopy.

They are actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 2 clinical trials.

Locations

Milan, Italy
Other Locations
Genoa, Italy
Via Manzoni 56, Milan, Rozzano, 20089, Italy
Pavia, 27100, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Enrollment Status: Terminated
Publish Date: November 21, 2022
Intervention Type: Drug
Study Drug: Deferasirox
Study Phase: Phase 2
View 1 Less Clinical Trial

38 Total Publications

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026

Frequently Asked Questions about Matteo D. Porta

Is Matteo D. Porta a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Matteo D. Porta is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Matteo D. Porta participate in research or clinical trials?

Yes. Matteo D. Porta has published 38 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Matteo D. Porta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Porta's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile